Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback